Quantitative Investment Management Has Trimmed Its Intuit (INTU) Holding; Dicerna Pharmaceuticals, Inc. (DRNA) Covered By 3 Bullish Analysts Last Week

December 6, 2017 - By Marie Mckinney

Quantitative Investment Management Llc decreased Intuit Inc (INTU) stake by 8.26% reported in 2017Q2 SEC filing. Quantitative Investment Management Llc sold 18,400 shares as Intuit Inc (INTU)’s stock rose

4.61%. The Quantitative Investment Management Llc holds 204,300 shares with $27.13 million value, down from 222,700 last quarter. Intuit Inc now has $39.93 billion valuation. The stock increased 1.11% or $1.72 during the last trading session, reaching $156.19. About 835,364 shares traded. Intuit Inc. (NASDAQ:INTU) has risen 23.62% since December 6, 2016 and is uptrending. It has outperformed by 6.92% the S&P500.

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus on Tuesday, May 10 with “Buy”. Stifel Nicolaus maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) rating on Thursday, June 30. Stifel Nicolaus has “Buy” rating and $13 target. The firm earned “Neutral” rating on Thursday, June 30 by Chardan Capital Markets. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given on Thursday, November 2 by Stifel Nicolaus. H.C. Wainwright maintained the stock with “Buy” rating in Friday, August 11 report. Chardan Capital Markets maintained the shares of DRNA in report on Monday, August 15 with “Neutral” rating. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Cowen & Co on Tuesday, July 18. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by H.C. Wainwright on Monday, December 12. The firm has “Outperform” rating given on Tuesday, September 8 by Cowen & Co. The rating was reinitiated by Leerink Swann on Tuesday, January 31 with “Mkt Perform”. See Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) latest ratings:

02/11/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $10.0 Maintain
16/08/2017 Broker: Cowen & Co Rating: Buy Maintain
11/08/2017 Broker: Chardan Capital Markets Rating: Hold Maintain
11/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0000 Maintain
18/07/2017 Broker: Cowen & Co Rating: Buy Maintain

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $165.54 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

The stock decreased 1.12% or $0.09 during the last trading session, reaching $7.94. About 180,676 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has declined 5.22% since December 6, 2016 and is downtrending. It has underperformed by 21.92% the S&P500.

Investors sentiment decreased to 0.55 in 2017 Q2. Its down 0.40, from 0.95 in 2017Q1. It fall, as 9 investors sold Dicerna Pharmaceuticals, Inc. shares while 11 reduced holdings. 4 funds opened positions while 7 raised stakes. 11.04 million shares or 3.09% more from 10.71 million shares in 2017Q1 were reported. Federated Invsts Incorporated Pa invested in 541 shares. Bancorporation Of America De stated it has 35 shares or 0% of all its holdings. Qs Invsts Ltd Co accumulated 1,071 shares. State Bank Of New York Mellon invested in 28,564 shares. Birchview L P holds 20,000 shares or 0.03% of its portfolio. Manufacturers Life Insurance Company The has invested 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). California Pub Employees Retirement Sys owns 41,000 shares or 0% of their US portfolio. Connor Clark And Lunn Inv Mgmt Ltd owns 79,275 shares for 0% of their portfolio. Jpmorgan Chase has 3,370 shares for 0% of their portfolio. Bridgeway Capital Mgmt Inc owns 93,300 shares. Palo Alto Investors Limited Co has invested 0.07% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Ecor1 Ltd Liability invested in 0.43% or 767,992 shares. The New York-based Blackrock Incorporated has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Dimensional Fund L P accumulated 0% or 32,024 shares. Vanguard Gp Inc holds 0% or 340,327 shares.

Quantitative Investment Management Llc increased Quintiles Ims Holdings Inc (NYSE:Q) stake by 262,600 shares to 311,300 valued at $27.86 million in 2017Q2. It also upped Huntington Bancshares Inc (NASDAQ:HBAN) stake by 638,500 shares and now owns 715,700 shares. Costco Wholesale Corp (NASDAQ:COST) was raised too.

Investors sentiment decreased to 0.96 in 2017 Q2. Its down 0.05, from 1.01 in 2017Q1. It worsened, as 41 investors sold INTU shares while 249 reduced holdings. 74 funds opened positions while 205 raised stakes. 215.33 million shares or 0.33% more from 214.62 million shares in 2017Q1 were reported. Roundview Capital Lc reported 1,585 shares or 0.06% of all its holdings. Shell Asset Mgmt Co holds 45,187 shares or 0.15% of its portfolio. Geode Capital Mngmt Ltd Liability Corporation has invested 0.14% in Intuit Inc. (NASDAQ:INTU). Meristem Limited Liability Partnership has invested 0.58% of its portfolio in Intuit Inc. (NASDAQ:INTU). Ajo Limited Partnership invested in 0.61% or 1.08 million shares. Rhumbline Advisers holds 0.13% or 414,737 shares in its portfolio. Dubuque Comml Bank And Tru accumulated 0% or 125 shares. Moreover, Winslow Cap Mngmt Ltd Limited Liability Company has 1.21% invested in Intuit Inc. (NASDAQ:INTU) for 1.71 million shares. Macquarie Grp Incorporated owns 740,985 shares. Fifth Third State Bank reported 0.02% in Intuit Inc. (NASDAQ:INTU). 1,899 were reported by 1St Source National Bank & Trust. Ledyard Financial Bank stated it has 0.01% of its portfolio in Intuit Inc. (NASDAQ:INTU). Buffington Mohr Mcneal holds 2,784 shares or 0.15% of its portfolio. Palisade Cap Mngmt Limited Nj has 5,465 shares for 0.03% of their portfolio. Jupiter Asset Management Limited holds 45,700 shares.

Among 22 analysts covering Intuit (NASDAQ:INTU), 9 have Buy rating, 2 Sell and 11 Hold. Therefore 41% are positive. Intuit had 76 analyst reports since August 10, 2015 according to SRatingsIntel. On Wednesday, August 24 the stock rating was maintained by UBS with “Buy”. The rating was upgraded by Wells Fargo on Thursday, September 21 to “Buy”. Oppenheimer maintained Intuit Inc. (NASDAQ:INTU) rating on Friday, October 27. Oppenheimer has “Buy” rating and $159.0 target. The firm earned “Buy” rating on Thursday, April 14 by Brean Capital. The stock has “Hold” rating by Zacks on Tuesday, August 25. The stock has “Buy” rating by Oppenheimer on Wednesday, August 23. As per Monday, August 10, the company rating was downgraded by Raymond James. The rating was maintained by Stifel Nicolaus with “Hold” on Friday, July 21. The stock has “Hold” rating by Stifel Nicolaus on Tuesday, November 21. The firm earned “Buy” rating on Saturday, August 22 by TheStreet.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>